Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD
Status:
Completed
Trial end date:
2015-11-19
Target enrollment:
Participant gender:
Summary
This study was designed to evaluate the efficacy and safety of two different regimens of 0.5
mg ranibizumab given as intravitreal injection in patients with neovascular age-related
macular degeneration